Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05029141 | New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 21 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05376111 | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | recruiting | Phase 2 | 28 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 |
| clinicaltrials |
| NCT06220162 | VAC Regimen for AML Patients Who Failed to Response to VA Regimen | recruiting | Phase 2 | 32 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06207123 | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | recruiting | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT05478512 | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL(VIS) | active not recruiting | Phase 2 | 78 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation(ACCELERATE) | recruiting | Phase 2 | 358 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06918431 | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 53 | City of Hope Medical CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04644016 | Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | recruiting | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06055621 | Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE(VEN-R DASA) | recruiting | Phase 2 | 35 | Institut Paoli-CalmettesOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06557421 | De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients(STOP VEN) | recruiting | Phase 2 | 50 | Institut Paoli-CalmettesOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471789 | Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). | recruiting | Phase 1 / Phase 2 | 33 | Gyala TherapeuticsINDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03970096 | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 120 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia(GRACE) | not yet recruiting | Phase 1 / Phase 2 | 50 | University of ManchesterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07463768 | Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.(MIVONU) | not yet recruiting | Phase 2 | 60 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | recruiting | Phase 2 | 216 | City of Hope Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06316856 | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05306301 | Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | active not recruiting | Phase 2 | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07060001 | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | not yet recruiting | Phase 2 | 112 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06253637 | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program(DARATALL-VHR) | active not recruiting | Phase 2 | 31 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05479994 | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 100 | BeiGeneINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07294677 | CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL(CAVALRY) | recruiting | Phase 1 / Phase 2 | 104 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07449286 | IFN-α in Relapse Prevention. | not yet recruiting | Phase 2 | 100 | Peking University People's HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05565105 | CD34+ Transplants for Leukemia and Lymphoma | not yet recruiting | Phase 2 | 100 | Guenther KoehneOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05873712 | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | recruiting | Phase 2 | 24 | Aseel AlsouqiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06483906 | Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | recruiting | Phase 2 | 56 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06511882 | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | recruiting | Phase 2 | 37 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437170 | Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | active not recruiting | Phase 2 | 10 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04624633 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | active not recruiting | Phase 2 | 29 | Jennifer R. Brown, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05580601 | Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05650723 | Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab | active not recruiting | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06773208 | A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07425808 | FLT3-ITD Targeted Therapy in Fit AML Patients(FIT-AML) | not yet recruiting | Phase 2 / Phase 3 | 230 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 23, 2026 | clinicaltrials |
| NCT07423104 | A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 24 | University of RochesterOTHER | 0 | Feb 20, 2026 | clinicaltrials |
| NCT00544466 | Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | active not recruiting | Phase 1 / Phase 2 | 75 | City of Hope Medical CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05336812 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 52 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06466122 | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | recruiting | Phase 2 | 30 | Kerry RogersOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04761770 | Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders | active not recruiting | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | active not recruiting | Phase 1 / Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03580928 | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL(AVO) | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 72 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2026source: clinicaltrials